Evaluation of characteristics of CD44+CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures

BMC Cell Biology

Jun Dou³  Hongyi Zhang³  Yunxia Zhang²  Cuiping Yang³  Jie Yang¹  Dengyu Chen³  Jing Wang²  Junsong Chen³ 

[1] Jiangsu Simcere Pharmaceutical R&D center, No.699-18 XUANWU Ave, Nanjing, 210042, China;Department of Gynecology & Obstetrics, Zhongda Hospital, Medical School, Southeast University, Dingjiaqiao 87, Nanjing, 210009, China;Department of Pathogenic Biology & Immunology, Medical School, Southeast University, Dingjiaqiao 87, Nanjing, 210009, China

关键词: Chemoresistance;    Cancer stem cells;    Epithelial ovarian cancer;    Three-dimensional culture;   

Others  :  855504
DOI  :  10.1186/1471-2121-14-7

 received in 2012-09-28, accepted in 2013-01-21,  发布年份 2013

【 摘 要 】

Background

Cancer stem cells (CSCs) are thought to be capable of surviving conventional chemotherapeutic treatments because the cells have more resistant to anticancer drugs than common cancer cells. Most in vitro studies in experimental cancer cells have been done in a two-dimensional (2D) monocultures, while accumulating evidence suggests that cancer cells behave differently when they are grown within a three-dimensional (3D) culture system.

Results

The CD44⁺CD117⁺cells isolated from human epithelial ovarian cancer SKOV-3 cell line using magnetic-activated cell sorting were found to grow faster than the SKOV-3 cells in the 3D culture and in the nude mice. Anticancer drugs 5FU, docetaxel, cisplatin, and carboplatin were seen to inhibit growth of the CD44⁺CD117⁺ cells by 50% in the 2D culture with IC₅₀ concentration, whereas, in the 3D culture, the four drugs inhibited the cell growth by only 34.4%, 40.8%, 34.8% and 21.9% at 3D one, respectively. Effect of paclitaxel on the CD44⁺CD117⁺cell viability indicated that fewer cells underwent apoptosis in 3D culture than that in 2D one. In addition, anticancer drugs markedly increased the expression of ABCG2 and ABCB1 of CD44⁺CD117⁺cells in 3D culture.

Conclusion

Our assay demonstrated that human epithelial ovarian cancer CD44⁺CD117⁺cells possessed the properties of CSCs that exhibited more chemoresistance in the 3D culture than that of in 2D one. The 3D culture provides a realistic model for study of the CSC response to anticancer drugs.

【 授权许可】

   
2013 Chen et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Cannistra SA: Cancer of the ovary. N Eng J Med 2004, 351:2519-2529.
• [2]Attar R, Attar E: Use of hematopoietic stem cells in obstetrics and gynecology. Transfus Apher Sci 2008, 38:245-251.
• [3]Ayhan A, Gultekin M, Dursun P, Dogan NU, Aksan G, Guven S, Velipasaoglu M, Yuce K: Metastatic lymph node number in epithelial ovarian carcinoma, does it have any clinical significance? Gynecol Oncol 2008, 108:428-432.
• [4]Bapat SA: Human ovarian cancer stem cells. Reproduction 2010, 140:33-41.
• [5]Jun D, Jing W, Ning G: Latest therapeutic approaches based on cancer stem cells. In Cancer stem cells - the cutting edge. Edited by Shostak S. New York, U.S.A: InTech Publishing; 2011:389-406.
• [6]Castelló-Cros R, Khan DR, Simons J, Valianou M, Cukierman E: Staged stromal extracellular 3D matrices differentially regulate breast cancer cell responses through PI3K and beta1-integrins. BMC Cancer 2009, 9:94. BioMed Central Full Text
• [7]Liu T, Cheng W, Lai D, Huang Y, Guo L: Ovarian cancer cells in different culture systems. Oncol Rep 2010, 23:1277-1284.
• [8]Singh A, Settleman J: EMT, cancer stem cells and drug resistance, an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751.
• [9]Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB: Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
• [10]Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008, 68:4311-4320.
• [11]Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007, 104:973-978.
• [12]Dalerba P, Cho RW, Clarke MF: Cancer stem cells, models and concepts. Annu Rev Med 2007, 58:267-284.
• [13]Celli JP, Rizvi I, Evans CL, Abu-Yousif AO, Hasan T: Quantitative imaging reveals heterogeneous growth dynamics and treatment-dependent residual tumor distributions in a three-dimensional ovarian cancer model. J Biomed Opt 2010, 15:051603.
• [14]Leeper AD, Farrell J, Williams LJ, Thomas JS, Dixon JM, Wedden SE, Harrison DJ, Katz E: Determining tamoxifen sensitivity using primary breast cancer tissue in collagen-based three-dimensional culture. Biomaterials 2012, 33:907-915.
• [15]Horning JL, Sahoo SK, Vijayaraghavalu S, Dimitrijevic S, Vasir JK, Jain TK, Panda AK, Labhasetwar V: 3-D tumor model for in vitro evaluation of anticancer drugs. Mol Pharm 2008, 5:849-862.
• [16]Chen L, Xiao Z, Meng Y, Zhao Y, Han J, Su G, Chen B, Dai J: The enhancement of cancer stem cell properties of MCF-7 cells in 3D collagen scaffolds for modeling of cancer and anti-cancer drugs. Biomaterials 2012, 33:1437-1444.
• [17]Arnhold S, Glüer S, Hartmann K, Raabe O, Addicks K, Wenisch S, Hoopmann M: Amniotic-fluid stem cells, growth dynamics and differentiation potential after a CD-117-based selection procedure. Stem Cells Int 2011, 23:715341.
• [18]Luo L, Zeng J, Liang B, Zhao Z, Sun L, Cao D, Yang J, Shen K: Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome. Exp Mol Pathol 2011, 91:596-602.
• [19]Choi YP, Shim HS, Gao MQ, Kang S, Cho NH: Molecular portraits of intratumoral heterogeneity in human ovarian cancer. Cancer Lett 2011, 307:62-71.
• [20]Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA, Daidone MG: Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005, 65:5506-5511.
• [21]Aoudjit F, Vuori K: Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001, 20:4995-5004.
• [22]Hodkinson PS, Elliott T, Wong WS, Rintoul RC, Mackinnon AC, Haslett C, Sethi T: ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death Differ 2006, 13:1776-1788.
• [23]Dou J, Jiang C, Wang J, Zhang X, Zhao F, Hu W, He X, Li X, Zou D, Gu N: Using ABCG2-molecule-expressing side population cells to identify cancer stem-like cells in a human ovarian cell line. Cell Biol Int 2011, 35:227-234.
• [24]Chambers I, Smith A: Self-renewal of teratocarcinoma and embryonic stem cells. Oncogene 2004, 23:7150-7160.
• [25]Seo K, Chung SW, Byun Y, Kim D: Paclitaxel loaded nano-aggregates based on pH sensitive polyaspartamide amphiphilic graft copolymers. Int J Pharm 2012, 424:26-32.
• [26]Dou J, Gu N: Biomarkers of cancer stem cells. In Advance in cancer stem cells. Edited by Scatena R, Mordente A, Giardina B. Rijeka, Croatia: InTech Publishing; 2011:45-68.
• [27]Zhang H, Wang J, Cai K, Jiang L, Zhou D, Yang C, Chen J, Chen D, Dou J: Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells. J Can Res Ther 2012, 8:226-231.
• [28]Berry NB, Bapat SA: Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype. J Ovarian Res 2008, 21:8-19.
• [29]Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, Marks JR, Berchuck A, Murphy SK: Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009, 28:209-218.
• [30]Vahidnezhad H, Youssefian L, Jeddi-Tehrani M, Akhondi MM, Rabbani H, Shokri F, Tabrizi M: Modeling breast acini in tissue culture for detection of malignant phenotype reversion to non-malignant phenotype. Iran Biomed J 2009, 13:191-198.
• [31]Quiros RM, Valianou M, Kwon Y, Brown KM, Godwin AK, Cukierman E: Ovarian normal and tumor-associated fibroblasts retain in vivo stromal characteristics in a 3-D matrix-dependent manner. Gynecol Oncol 2008, 110:99-109.
• [32]Fekete M, Santiskulvong C, Eng C, Dorigo O: Effect of PI3K/Akt pathway inhibition- mediated G1 arrest on chemosensitization in ovarian cancer cells. Anticancer Res 2012, 32:445-452.
• [33]Ong SM, Zhao Z, Arooz T, Zhao D, Zhang S, Du T, Wasser M, van Noort D, Yu H: Engineering a scaffold-free 3D tumor model for in vitro drug penetration studies. Biomaterials 2010, 31:1180-1190.
• [34]Finger EC, Giaccia AJ: Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev 2010, 29:285-293.
• [35]Michael D, Tito F, Susan B: Tumor stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284.
• [36]Hoei-Hansen CE, Almstrup K, Nielsen JE, Brask Sonne S, Graem N, Skakkebaek NE, Leffers H, Rajpert-De Meyts E: Stem cell pluripotency factor Nanog is expressed in human fetal gonocytes, testicular carcinoma in situ and germ cell tumours. Histopathology 2005, 47:48-56.